Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11143011 | 0.98 | GAA (0.46) | GAATSHRMAPK1CAMK2ACYP4F2 | |
| SCHEMBL22266272 | 0.93 | GAA (0.55) | GAATSHRMAPK1CAMK2ACYP4F2 | |
| SCHEMBL22266240 | 0.93 | GAA (0.48) | GAATSHRMAPK1CAMK2ACYP4F2 | |
| SCHEMBL20325130 | 0.91 | GAA (0.58) | GAATSHRMAPK1CAMK2ACYP4F2 | |
| SCHEMBL22266255 | 0.91 | GAA (0.57) | GAATSHRMAPK1CAMK2ACYP4F2 | |
| SCHEMBL10706576 | 0.88 | GAA (0.60) | GAATSHRMAPK1CAMK2ACYP4F2 | |
| SCHEMBL22266248 | 0.88 | GAA (0.60) | GAATSHRMAPK1CAMK2ACYP4F2 | |
| SCHEMBL22266241 | 0.88 | TSHR (0.46) | GAATSHRMAPK1CYP4F2CYP4A11 | |
| SCHEMBL1656554 | 0.87 | GAA (0.42) | GAATSHRMEN1KMT2ATHRB | |
| SCHEMBL31494110 | 0.87 | GAA (0.38) | GAATSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | GAA 1531/4885TSHR 2304/4885MAPK1 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.